92.9 F
San Fernando
Friday, Dec 1, 2023

Amgen Seeks Approval for Leukemia Drug

Amgen Inc. announced on Monday that it is seeking regulatory approval to sell a drug for treating a rare and particularly deadly form of leukemia. The Thousand Oaks biopharmaceutical company has submitted an application to the Food and Drug Administration for blinatumomab, which helps the human body recognize cancer cells in the blood. Amgen wants permission for the drug to treat people with acute lymphoblastic leukemia. About 6,000 cases of the condition are diagnosed annually in the United States, and about 7,000 in Europe. In adult patients with a relapse of the disease, average survival is only three to five months. Dr. Sean Harper, executive vice president of research and development at Amgen, said the filing for blinatumomab represents the company’s commitment to find treatments difficult types of cancer. “We look forward to working with regulatory authorities to make blinatumomab available for adult patients with acute lymphoblastic leukemia, who experience high relapse rates and have limited treatment options,” he said in a statement. Shares closed down $1.83, or 1.3 percent, to $142.18 on the Nasdaq.

Joel Russel
Joel Russel
Joel Russell joined the Los Angeles Business Journal in 2006 as a reporter. He transferred to sister publication San Fernando Valley Business Journal in 2012 as managing editor. Since he assumed the position of editor in 2015, the Business Journal has been recognized four times as the best small-circulation tabloid business publication in the country by the Alliance of Area Business Publishers. Previously, he worked as senior editor at Hispanic Business magazine and editor of Business Mexico.

Featured Articles

Related Articles